New combo targets resistant lung cancer in early trial

NCT ID NCT07486648

Not yet recruiting Disease control Sponsor: Shanxi Province Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Mar 29, 2026 · Last updated May 23, 2026 · Updated 7 times

Summary

This early-phase trial tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has stopped responding to first-line osimertinib. About 53 adults with certain genetic changes (PIK3CA/AKT1/PTEN) will receive the two drugs together. The study first finds a safe dose, then measures how many patients' tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER NON SMALL CELL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shanxi Cancer Hospital

Taiyuan, Shanxi, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED NON-SMALL CELL LUNG CANCER LUNG CANCER (NSCLC) LUNG CANCER NON SMALL CELL